SH3BP5L
gene geneOn this page
Also known as KIAA1720
Summary
SH3BP5L (SH3 binding domain protein 5 like, HGNC:29360) is a protein-coding gene on chromosome 1q44, encoding SH3 domain-binding protein 5-like (Q7L8J4). Functions as a guanine nucleotide exchange factor (GEF) for RAB11A.
Enables guanyl-nucleotide exchange factor activity. Predicted to be involved in intracellular signal transduction. Predicted to be active in cytoplasm.
Source: NCBI Gene 80851 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 57 total
- MANE Select transcript:
NM_030645
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:29360 |
| Approved symbol | SH3BP5L |
| Name | SH3 binding domain protein 5 like |
| Location | 1q44 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | KIAA1720 |
| Ensembl gene | ENSG00000175137 |
| Ensembl biotype | protein_coding |
| OMIM | 620652 |
| Entrez | 80851 |
Gene structure
Transcript identifiers
Ensembl transcripts: 15 — 12 protein_coding, 3 protein_coding_CDS_not_defined
ENST00000366472, ENST00000475978, ENST00000484202, ENST00000494837, ENST00000870257, ENST00000870258, ENST00000870259, ENST00000870260, ENST00000870261, ENST00000931893, ENST00000931894, ENST00000931895, ENST00000931896, ENST00000931897, ENST00000966015
RefSeq mRNA: 4 — MANE Select: NM_030645
NM_001322462, NM_001322463, NM_001322464, NM_030645
CCDS: CCDS31126
Canonical transcript exons
ENST00000366472 — 7 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001276497 | 248825835 | 248825915 |
| ENSE00001441809 | 248824753 | 248825366 |
| ENSE00001833074 | 248810446 | 248812370 |
| ENSE00003576778 | 248812989 | 248813162 |
| ENSE00003621119 | 248814449 | 248814610 |
| ENSE00003662494 | 248816534 | 248816662 |
| ENSE00003681884 | 248816822 | 248816884 |
Expression profiles
Bgee: expression breadth ubiquitous, 225 present calls, max score 93.28.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.7116 / max 47.7928, expressed in 1739 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 18526 | 3.8789 | 1597 |
| 18527 | 2.7888 | 1306 |
| 18525 | 0.0440 | 18 |
Top tissues by expression
249 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| lower esophagus mucosa | UBERON:0035834 | 93.28 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 90.80 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 90.51 | gold quality |
| cerebellar cortex | UBERON:0002129 | 90.37 | gold quality |
| granulocyte | CL:0000094 | 90.12 | gold quality |
| apex of heart | UBERON:0002098 | 89.86 | gold quality |
| stromal cell of endometrium | CL:0002255 | 89.47 | gold quality |
| right frontal lobe | UBERON:0002810 | 89.38 | gold quality |
| cerebellum | UBERON:0002037 | 89.24 | gold quality |
| gastrocnemius | UBERON:0001388 | 88.91 | gold quality |
| prefrontal cortex | UBERON:0000451 | 88.80 | gold quality |
| muscle of leg | UBERON:0001383 | 88.56 | gold quality |
| cortical plate | UBERON:0005343 | 88.36 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 88.34 | gold quality |
| lower esophagus | UBERON:0013473 | 88.18 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 88.16 | gold quality |
| blood | UBERON:0000178 | 88.08 | gold quality |
| right uterine tube | UBERON:0001302 | 87.97 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 87.70 | gold quality |
| esophagus mucosa | UBERON:0002469 | 87.67 | gold quality |
| esophagus | UBERON:0001043 | 87.65 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 87.33 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 87.32 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 87.01 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 86.88 | gold quality |
| right adrenal gland | UBERON:0001233 | 86.82 | gold quality |
| metanephros cortex | UBERON:0010533 | 86.67 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 86.66 | gold quality |
| right lobe of liver | UBERON:0001114 | 86.50 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 86.48 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 3.05 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
77 targeting SH3BP5L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4476 | 100.00 | 68.18 | 2030 |
| HSA-MIR-6876-5P | 100.00 | 67.68 | 2126 |
| HSA-MIR-29A-3P | 100.00 | 73.11 | 1835 |
| HSA-MIR-29B-3P | 100.00 | 73.18 | 1833 |
| HSA-MIR-29C-3P | 100.00 | 73.15 | 1833 |
| HSA-MIR-548AA | 99.96 | 70.64 | 3753 |
| HSA-MIR-548AP-3P | 99.96 | 70.64 | 3753 |
| HSA-MIR-548T-3P | 99.96 | 70.64 | 3753 |
| HSA-MIR-4725-3P | 99.96 | 69.53 | 2520 |
| HSA-MIR-6780B-5P | 99.96 | 69.60 | 2562 |
| HSA-MIR-548AB | 99.95 | 71.31 | 3488 |
| HSA-MIR-559 | 99.95 | 72.28 | 3609 |
| HSA-MIR-548Y | 99.94 | 71.28 | 3514 |
| HSA-MIR-548A-5P | 99.94 | 71.27 | 3482 |
| HSA-MIR-548AD-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548AE-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548AK | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AM-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AP-5P | 99.94 | 71.14 | 3489 |
| HSA-MIR-548AQ-5P | 99.94 | 71.34 | 3426 |
| HSA-MIR-548AR-5P | 99.94 | 71.28 | 3515 |
| HSA-MIR-548AS-5P | 99.94 | 71.22 | 3482 |
| HSA-MIR-548AU-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AY-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548B-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548BB-5P | 99.94 | 71.27 | 3509 |
| HSA-MIR-548C-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548D-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548H-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548I | 99.94 | 71.25 | 3481 |
Cross-species orthologs
7 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | sh3bp5lb | ENSDARG00000007136 |
| danio_rerio | sh3bp5la | ENSDARG00000019160 |
| mus_musculus | Sh3bp5l | ENSMUSG00000013646 |
| rattus_norvegicus | Sh3bp5l | ENSRNOG00000054400 |
| drosophila_melanogaster | pcs | FBGN0033988 |
| caenorhabditis_elegans | WBGENE00007270 | |
| caenorhabditis_elegans | WBGENE00019365 |
Paralogs (1): SH3BP5 (ENSG00000131370)
Protein
Protein identifiers
SH3 domain-binding protein 5-like — Q7L8J4 (reviewed: Q7L8J4)
All UniProt accessions (1): Q7L8J4
UniProt curated annotations — full annotation on UniProt →
Function. Functions as a guanine nucleotide exchange factor (GEF) for RAB11A.
Similarity. Belongs to the SH3BP5 family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q7L8J4-1 | 1 | yes |
| Q7L8J4-2 | 2 |
RefSeq proteins (4): NP_001309391, NP_001309392, NP_001309393, NP_085148* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR007940 | SH3BP5 | Family |
Pfam: PF05276
UniProt features (19 total): modified residue 8, compositionally biased region 4, region of interest 3, coiled-coil region 2, chain 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q7L8J4-F1 | 74.38 | 0.52 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (8): 13, 30, 49, 343, 350, 358, 362, 378
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 104 (showing top):
TGGTGCT_MIR29A_MIR29B_MIR29C, SP3_Q3, AP2_Q3, RYTTCCTG_ETS2_B, WHN_B, AML1_01, TGCCTTA_MIR124A, chr1q44, GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN, GOMF_GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY, GOMF_NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY, GOMF_ENZYME_INHIBITOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, BRUINS_UVC_RESPONSE_LATE, STAT6_01
GO Biological Process (1): intracellular signal transduction (GO:0035556)
GO Molecular Function (3): protein kinase inhibitor activity (GO:0004860), guanyl-nucleotide exchange factor activity (GO:0005085), protein binding (GO:0005515)
GO Cellular Component (1): cytoplasm (GO:0005737)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| intracellular anatomical structure | 2 |
| signal transduction | 1 |
| protein kinase activity | 1 |
| kinase inhibitor activity | 1 |
| protein kinase regulator activity | 1 |
| GTP binding | 1 |
| GDP binding | 1 |
| GTPase regulator activity | 1 |
| binding | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
1142 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| SH3BP5L | CLSTN3 | Q9BQT9 | 460 |
| SH3BP5L | CDH18 | Q13634 | 454 |
| SH3BP5L | TELO2 | Q9Y4R8 | 447 |
| SH3BP5L | RAB11FIP3 | O75154 | 444 |
| SH3BP5L | ZNF672 | Q499Z4 | 433 |
| SH3BP5L | SPATA45 | Q537H7 | 419 |
| SH3BP5L | OR6K3 | Q8NGY3 | 419 |
| SH3BP5L | SNCAIP | Q9Y6H5 | 415 |
| SH3BP5L | CCDC122 | Q5T0U0 | 414 |
| SH3BP5L | ZNF670 | Q9BS34 | 398 |
| SH3BP5L | NEDD9 | Q14511 | 390 |
| SH3BP5L | RNF146 | Q9NTX7 | 381 |
| SH3BP5L | PLA2G6 | O60733 | 375 |
| SH3BP5L | CCDC137 | Q6PK04 | 373 |
| SH3BP5L | CYSRT1 | A8MQ03 | 369 |
IntAct
58 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| YWHAG | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.810 |
| RAB11B | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.740 |
| YWHAZ | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.670 |
| RAB11B | SH3BP5 | psi-mi:“MI:0914”(association) | 0.640 |
| YWHAG | BLTP3B | psi-mi:“MI:0914”(association) | 0.640 |
| YWHAH | PLEKHG3 | psi-mi:“MI:0914”(association) | 0.610 |
| EMC2 | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.560 |
| SH3BP5L | CEP57 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SH3BP5L | FAM161B | psi-mi:“MI:0915”(physical association) | 0.560 |
| RAB14 | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.560 |
| SUOX | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.560 |
| RAB25 | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCK | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.560 |
| SH3GLB1 | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.560 |
| PRPF40A | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.560 |
| RAB11A | SH3BP5 | psi-mi:“MI:0914”(association) | 0.530 |
| YWHAQ | IGLC7 | psi-mi:“MI:0914”(association) | 0.530 |
| YWHAB | PLEKHG3 | psi-mi:“MI:0914”(association) | 0.480 |
| YWHAQ | PLEKHG3 | psi-mi:“MI:0914”(association) | 0.480 |
| NINL | SH3BP5L | psi-mi:“MI:0915”(physical association) | 0.370 |
| SH3BP5L | PPP1R12A | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (59): SH3BP5L (Affinity Capture-MS), SH3BP5L (Two-hybrid), BICD1 (Affinity Capture-MS), THG1L (Affinity Capture-MS), TNKS (Affinity Capture-MS), TNKS2 (Affinity Capture-MS), BTRC (Affinity Capture-MS), SH3BP5L (Affinity Capture-MS), SH3BP5L (Affinity Capture-MS), PPP1R12A (Affinity Capture-MS), HEXIM1 (Affinity Capture-MS), MIPOL1 (Affinity Capture-MS), FBXW11 (Affinity Capture-MS), CARM1 (Affinity Capture-MS), WTAP (Affinity Capture-MS)
ESM2 similar proteins: A0PJT0, A1YB07, A2A6T1, A4IH82, B1A193, D3ZD05, O14526, O60239, O75145, O75335, O94876, P60469, P84903, Q0V8K7, Q13136, Q1LU99, Q1LZH7, Q2QL82, Q2QLG9, Q3TBD2, Q495M9, Q58CP9, Q5R9X9, Q5RB40, Q5U4W1, Q5U584, Q63ZY3, Q69ZZ6, Q6AYB8, Q6DIS8, Q6NZT2, Q6P402, Q7L8J4, Q80T11, Q86YS3, Q8BIJ7, Q8BQP8, Q8BX02, Q8CJ96, Q91Y80
Diamond homologs: A4IH82, O60239, Q0V8K7, Q21194, Q5R9X9, Q5U584, Q7L8J4, Q91Y80, Q99LH9, Q9V785, Q9Z131, P42171
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 29 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Activation of BAD and translocation to mitochondria | 5 | 190.3× | 8e-10 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 5 | 167.9× | 1e-09 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 5 | 167.9× | 1e-09 |
| Activation of BH3-only proteins | 5 | 124.1× | 5e-09 |
| RHO GTPases activate PKNs | 6 | 95.2× | 8e-10 |
| Intrinsic Pathway for Apoptosis | 5 | 73.2× | 8e-08 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 7 | 54.0× | 8e-10 |
| SARS-CoV-1-host interactions | 5 | 43.9× | 1e-06 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| intracellular protein localization | 5 | 20.1× | 4e-04 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
57 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 47 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1267 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 1:248812990:T:TA | donor_gain | 1.0000 |
| 1:248814444:CTCA:C | donor_loss | 1.0000 |
| 1:248814446:CACCT:C | donor_loss | 1.0000 |
| 1:248814447:A:AC | donor_gain | 1.0000 |
| 1:248814448:C:CC | donor_gain | 1.0000 |
| 1:248814448:C:CT | donor_loss | 1.0000 |
| 1:248814448:CCTTG:C | donor_gain | 1.0000 |
| 1:248814606:TGAGC:T | acceptor_gain | 1.0000 |
| 1:248814608:AGC:A | acceptor_gain | 1.0000 |
| 1:248814609:GC:G | acceptor_gain | 1.0000 |
| 1:248814610:CC:C | acceptor_gain | 1.0000 |
| 1:248814611:C:CC | acceptor_gain | 1.0000 |
| 1:248816530:ATACC:A | donor_loss | 1.0000 |
| 1:248816531:TACC:T | donor_loss | 1.0000 |
| 1:248816532:ACC:A | donor_loss | 1.0000 |
| 1:248816532:ACCT:A | donor_gain | 1.0000 |
| 1:248816533:CCTC:C | donor_gain | 1.0000 |
| 1:248816535:T:TA | donor_gain | 1.0000 |
| 1:248816658:GCCTC:G | acceptor_gain | 1.0000 |
| 1:248816659:CCTCC:C | acceptor_gain | 1.0000 |
| 1:248816660:CTC:C | acceptor_gain | 1.0000 |
| 1:248816661:TC:T | acceptor_gain | 1.0000 |
| 1:248816662:CC:C | acceptor_gain | 1.0000 |
| 1:248816663:C:CC | acceptor_gain | 1.0000 |
| 1:248816663:CTGG:C | acceptor_loss | 1.0000 |
| 1:248816664:T:A | acceptor_loss | 1.0000 |
| 1:248816674:C:CT | acceptor_gain | 1.0000 |
| 1:248816675:A:T | acceptor_gain | 1.0000 |
| 1:248816817:CTCA:C | donor_loss | 1.0000 |
| 1:248816818:TCA:T | donor_loss | 1.0000 |
AlphaMissense
2527 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 1:248812268:G:C | H272D | 1.000 |
| 1:248812268:G:T | H272N | 1.000 |
| 1:248812270:A:G | I271T | 1.000 |
| 1:248812278:G:C | S268R | 1.000 |
| 1:248812278:G:T | S268R | 1.000 |
| 1:248812280:T:G | S268R | 1.000 |
| 1:248812282:A:C | I267S | 1.000 |
| 1:248812282:A:G | I267T | 1.000 |
| 1:248812291:A:G | L264P | 1.000 |
| 1:248812291:A:T | L264Q | 1.000 |
| 1:248812300:A:G | L261P | 1.000 |
| 1:248812300:A:T | L261H | 1.000 |
| 1:248812320:C:A | K254N | 1.000 |
| 1:248812320:C:G | K254N | 1.000 |
| 1:248812322:T:C | K254E | 1.000 |
| 1:248812993:A:G | L236P | 1.000 |
| 1:248813017:A:G | L228P | 1.000 |
| 1:248813022:A:C | F226L | 1.000 |
| 1:248813022:A:T | F226L | 1.000 |
| 1:248813023:A:C | F226C | 1.000 |
| 1:248813023:A:G | F226S | 1.000 |
| 1:248813024:A:G | F226L | 1.000 |
| 1:248813024:A:T | F226I | 1.000 |
| 1:248813027:A:C | Y225D | 1.000 |
| 1:248813044:A:T | I219N | 1.000 |
| 1:248813090:C:G | A204P | 1.000 |
| 1:248813153:C:G | A183P | 1.000 |
| 1:248814449:C:A | K179N | 1.000 |
| 1:248814449:C:G | K179N | 1.000 |
| 1:248814459:G:T | A176D | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000285507 (1:248814140 T>TA), RS1000603834 (1:248811366 G>A,C), RS1000808697 (1:248811125 G>A), RS1000903703 (1:248818098 A>T), RS1000977060 (1:248827552 C>T), RS1001265737 (1:248813912 G>C,T), RS1001895463 (1:248817862 A>T), RS1001925212 (1:248824327 G>A), RS1002079055 (1:248812395 G>A,C), RS1002121217 (1:248813282 C>A), RS1002150793 (1:248813562 A>G), RS1002298778 (1:248825595 C>T), RS1002413396 (1:248825323 GGC>G), RS1002593441 (1:248819097 C>A,G,T), RS1002661525 (1:248827037 G>A)
Disease associations
OMIM: gene MIM:620652 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST002935_1 | Lead levels | 2.000000e-07 |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
21 total (human), top 21 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | increases expression | 2 |
| aristolochic acid I | increases expression | 1 |
| FR900359 | affects phosphorylation | 1 |
| triphenyl phosphate | affects expression | 1 |
| beta-lapachone | increases expression | 1 |
| ferrous chloride | decreases expression | 1 |
| aflatoxin B2 | decreases methylation | 1 |
| coumarin | decreases phosphorylation | 1 |
| beta-methylcholine | affects expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| corosolic acid | increases expression | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| Leflunomide | decreases expression | 1 |
| Air Pollutants | affects expression, increases abundance | 1 |
| Estradiol | affects expression | 1 |
| Ozone | affects expression, increases abundance | 1 |
| Smoke | decreases expression | 1 |
| Tretinoin | increases expression | 1 |
| Urethane | increases expression | 1 |
| Cadmium Chloride | increases expression | 1 |
| Copper Sulfate | increases expression | 1 |
Cellosaurus cell lines
2 cell lines: 2 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_TK95 | HAP1 SH3BP5L (-) 1 | Cancer cell line | Male |
| CVCL_XS76 | HAP1 SH3BP5L (-) 2 | Cancer cell line | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.